Drug of Abuse (DOA)
Methadone (MTD) Rapid Test
Detects Methadone. colloidal-gold. Specimen: Urine.
| Target / Analyte | Methadone |
|---|---|
| Disease / Indication | Drug screening |
| Series | Drug of Abuse (DOA) |
| Method | colloidal-gold |
| Specimen | Urine |
| Test time | 10–15 min (product-specific) |
| Storage | 2–30 °C, sealed pouch with desiccant |
| Shelf life | 24 months (product-specific) |
| Regulatory | Non-CE / registration in progress |
| OEM/ODM | Available — private label & custom panel |
Direct Answer
This rapid test detects Methadone in Urine to support Drug screening. It is a colloidal-gold screening test — a reactive result is presumptive and should be confirmed per the intended use.
Intended Use
Detection of methadone (MTD) in urine.
Clinical Context
Methadone screening in opioid treatment programs and workplace testing; cut-off 300 ng/mL.
Test Principle
Colloidal-gold immunochromatography (lateral flow). The device captures the target analyte (antigen or antibody) on a membrane via labeled antibodies, producing a visible test line within minutes. Qualitative or semi-quantitative, intended as a screening/triage aid — not a replacement for confirmatory laboratory testing.
Limitations
Presumptive positive requires confirmation.
Procurement
Specimen: urine. Format: cassette / dipstick. CE-marked line.
Interpretation
| Result | Lines | Meaning |
|---|---|---|
| Positive | Test + control line | Target detected (presumptive positive) |
| Negative | Control line only | Below cut-off / not detected |
| Invalid | No control line | Repeat with a new device |
Common misconception
A reactive drug-screen result is presumptive — it does not indicate impairment, timing of use or a diagnosis. Confirm positives by GC-MS/LC-MS.
Sources
Screening results are presumptive, not diagnostic. Confirmatory testing follows WHO, CDC and national regulatory guidance — see screening vs confirmatory.
Available SKUs (this series)
| Cat. No. | Product | Specimen | Format | Kit Size | Status |
|---|---|---|---|---|---|
| DMT-102 | Methadone (MTD) Rapid Test Cassette | Urine | Cassette | 40 T | CE |
| DMT-114 | Methadone (MTD) Rapid Test Panel | Urine | Panel | 40 T | CE |
| DMT-101 | Methadone (MTD) Rapid Test Dipstick | Urine | Dipstick | 50 T | CE |
| DMT-802 | Methadone (MTD) Rapid Test Cassette | Oral Fluid | Cassette | 25 T | CE |
| DMT-803 | Methadone (MTD) Rapid Test Midstream | Oral Fluid | Midstream | 25 T | CE |
Technical Evidence
| Analytical performance | Sensitivity, specificity, cut-off and precision are documented per product line in the datasheet and validation report. |
|---|---|
| Average accuracy | ≥96% (overall agreement rate, manufacturer-validated). Per-product sensitivity and specificity are documented in the datasheet. |
| Clinical performance | Evaluation data (study population, reference method, agreement) available on request. |
| Cross-reactivity | Documented per analyte — see limitations above. |
| Documents | IFU · Datasheet · Certificate · Declaration of Conformity — request below. |
Buyer Information
| MOQ | Product-dependent — low MOQ available on specialty assays |
|---|---|
| OEM / private label | Custom branding, cut-off, panel and packaging |
| Samples | Available for evaluation — request via RFQ |
| Lead time | On request |
| Documents | IFU · Datasheet · COA · Validation report · CE files · Registration support |
Related knowledge
Documentation & quotation — datasheet, IFU, certificate, MOQ and OEM/ODM options on request.
Request IFU / Spec Sheet Request Datasheet Request Certificate
Last reviewed: 2026-09-12